Papel da monitorização prolongada no diagnóstico da Fibrilação Arterial


Rogério Andalaft

Médico assistente setor de Eletrofisiologia do Instituto Dante Pazzanese de Cardiologia Médico Hospital Israelita Albert Einstein Faculty American Heart Association






Distribuição da Demográfica da Fibrilação Atrial por Idade



Feinberg WM. Arch Intern Med. 1995;155:469-473.


Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence

Yoko Miyasaka, MD, PhD; Marion E. Barnes, MSc; Bernard J. Gersh, MB, ChB, DPhil; Stephen S. Cha, MS; Kent R. Bailey, PhD; Walter P. Abhayaratna, MBBS; James B. Seward, MD; Teresa S.M. Tsang, MD



Circulation 2006; 114:119-126

Mortalidade em Pacientes com FA



Benjamin JE et al. Circulation 1998; 98:946

Recomendações para Anticoagulação na Fibrilação Atrial


1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	L. E. V. Perla	The second of
Critério CHADS2*	Escore de ris	СО
História prévia de AVC		2
Idade > 75 anos		1/521
Hipertensão	CIE /	/ - /
Diabetes		1/1
Insuficiência cardíaca		7/ 1
	8 8 2 1 1 1 W. W.	1

^{*}Cardiac failure-Hypertension-Age-Diabetes-Stroke Pontuação acima de 2 → anticoagulação


Decidindo sobre anticoagulação

CHA ₂ DS ₂ -VASc	Score	HAS-BLED	Score
Congestive heart failure/LV dysfunction	1	Hypertension (systolic blood pressure >160 mm Hg)	1
Hypertension	1	Abnormal renal or liver function	1 or 2
Age ≥75 y	2	Stroke	1
Diabetes mellitus	1	Bleeding tendency or predisposition	1
Stroke/TIA/TE	2	Labile INR (if on warfarin)	1
Vascular disease (prior MI, PAD, or aortic plaque)	1	Age (eg, >65 y, frail condition)	1
Age 65–74 y Sex category (ie, female gender)	1	Drugs (eg, concomitant antiplatelet or NSAIDs) or alcohol excess/abuse	1 or 2
Maximum score	9		9

Data from Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010;137(2):263–72; and Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138(5):1093–100.







Restabelecimento do ritmo sinusal previne?

Locais mais comuns para tromboembolismo na fibrilação atrial


Autor	No.	Cerebral M	Visceral	
16	311	(%)	(%)	(%)
Szekeley	89	70	25	4
Fleming	173	66	20	14
Wood		75	33	6
Casella	21	55	15	27
Daley	393	48	38	14
Gazenge	257	82	13	4
Hinton	34	65	20	15
Hinton	73	58	25	18
Aberg	79	33	25	42
Aberg	308	53	16	31

Os caminhos a serem percorridos


Fibrilação Atrial CHADS2 CHADS2Vasc

AIT AVC

Os caminhos a serem percorridos



FA e Eventos isquemicos cerebrais



Cerebral Embolism Task Force. Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. *Arch Neurol* 1989; **46: 727–43.**Stroke Risk in Atrial Fibrillation Working Group, Independent


Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fi brillation: a systematic review. *Neurology 2007;* **69: 546–54**

Avaliação do Ritmo Cardíaco AVC isquêmico de causa não definida


- Monitorização eletrocardiográfica seriada
 - Monitorização com Holter
- Monitorização prolongada 30 dia (class IIa, evidência C)
 - Monitor de eventos externos
 - Monitor de eventos implantável
 - Telemetria ambulatorial


SISTEMA TELE-ECG IDPC

Equipamento de Transmissão do Tele-ECG (com duas operadoras de celular)




Rede de unidades de saúde da SES atendida no Estado de São Paulo






Distribuição das arritmias n= 462815 exames

Presença de arritmias supraventriculares ou ventriculares



Andalaft, R; França F, Almeida C et al – Relampa 2013


Distribuição das arritmias atriais




Andalaft, R; França F, Almeida C et al – Relampa 2013

Quantos dias em média levamos para iniciar a investigação







Resumo 7 dias

Nº do Exame	Paciente:	Código:
5859780	Data do Exame:	1J4-00017

Data	FC Min.	FC Méd.	FC Máx.	V iso.	V par.	Total V	SV iso.	SV par.	Total SV	Pausas	> Pausa	% Artefato	> Depr. ST	Inclin. ST	Depr. Cn
25/01/2015	46	76	151	378	35	475	91	153	511	17	7,8	18 %			
26/01/2015	54	82	141	438	31	509	123	171	548	4	4,3	19 %			
27/01/2015	52	81	145	108	10	128	37	61	182	2	3,2	6 %			
28/01/2015	49	82	144	84	5	94	45	48	238	9	4,7	2 %			
29/01/2015	46	87	163	90	5	100	92	114	571	2	19,1	4 %			
30/01/2015	54	87	145	23	0	23	14	11	56	3	2,9	< 1 %			
31/01/2015	53	85	144	15	1	17	10	11	129	0		< 1 %			
Total	46	83	163	1136	87	1346	412	569	2235	37	19	7 %			


Data	Taq. V	TV maior	TV mais rápida	TV mais lenta	aq. S	TSV maior	TSV mais rápida	TSV mais lenta	
25/01/2015	8	5 bat., 125 bpm 05:25:28	3 bat., 180 bpm 02:45:50	4 bat., 92 bpm 04:18:14	24	13 bat., 124 bpm 16:38:02	3 bat., 216 bpm 09:01:37	5 bat., 88 bpm 17:10:44	
26/01/2015	3	3 bat., 233 bpm 21:40:02	3 bat., 233 bpm 21:40:02	3 bat., 123 bpm 04:35:40	21	8 bat., 97 bpm 17:34:13	3 bat., 250 bpm 18:38:11	4 bat., 94 bpm 15:43:03	
27/01/2015	0				3	15 bat., 93 bpm 12:51:40	3 bat., 233 bpm 16:30:07	5 bat., 90 bpm 12:52:20	
28/01/2015	0				17	16 bat., 91 bpm 12:29:01	4 bat., 205 bpm 22:55:55	10 bat., 90 bpm 12:37:21	
29/01/2015	0				38	18 bat., 91 bpm 17:53:12	4 bat., 188 bpm 02:11:33	6 bat., 87 bpm 13:47:38	
30/01/2015	0				3	14 bat., 102 bpm 16:59:40	3 bat., 159 bpm 06:01:12	14 bat., 102 bpm 16:59:40	
31/01/2015	0				7	35 bat., 94 bpm 16:32:14	3 bat., 150 bpm 10:29:24	9 bat., 93 bpm 07:26:06	
Total	11	5 bat., 125 bpm 05:25:28	3 bat., 233 bpm 21:40:02	4 bat., 92 bpm 04:18:14	113	35 bat., 94 bpm 16:32:14	3 bat., 250 bpm 18:38:11	6 bat., 87 bpm 13:47:38	

Looper com transmissão via internet





Looper com transmissão via internet



The NEW ENGLAND JOURNAL of MEDICINE


ESTABLISHED IN 1812

JUNE 26, 2014

VOL. 370 NO. 26

Atrial Fibrillation in Patients with Cryptogenic Stroke

David J. Gladstone, M.D., Ph.D., Melanie Spring, M.D., Paul Dorian, M.D., Val Panzov, M.D., Kevin E. Thorpe, M.Math., Judith Hall, M.Sc., Haris Vaid, B.Sc., Martin O'Donnell, M.B., Ph.D., Andreas Laupacis, M.D., Robert Côté, M.D., Mukul Sharma, M.D., John A. Blakely, M.D., Ashfaq Shuaib, M.D., Vladimir Hachinski, M.D., D.Sc., Shelagh B. Coutts, M.B., Ch.B., M.D., Demetrios J. Sahlas, M.D., Phil Teal, M.D., Samuel Yip, M.D., J. David Spence, M.D., Brian Buck, M.D., Steve Verreault, M.D., Leanne K. Casaubon, M.D., Andrew Penn, M.D., Daniel Selchen, M.D., Albert Jin, M.D., David Howse, M.D., Manu Mehdiratta, M.D., Karl Boyle, M.B., B.Ch., Richard Aviv, M.B., Ch.B., Moira K. Kapral, M.D., and Muhammad Mamdani, Pharm.D., M.P.H., for the EMBRACE Investigators and Coordinators*



Incremento diagnóstico com o prolongamento da monitorização


The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

JUNE 26, 2014

Atrial Fibrillation in Patients with Cryptogenic Stroke





Duração da monitorização ECG

INTERNAL MEDICINE JOURNAL



Brief Communications

Twenty-eight day Holter monitoring is poorly tolerated and insensitive for paroxysmal atrial fibrillation detection in cryptogenic stroke

H. T. Tu,^{1,2} S. Spence,³ J. M. Kalman^{1,3} and S. M. Davis^{1,2}

¹University Department of Medicine, Departments of ²Neurology and ³Cardiology, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia

Key words

atrial fibrillation, stroke, Holter monitoring, diagnosis, screening.

Correspondence

Stephen M. Davis, Department of Neurology, The Royal Melbourne Hospital, Grattan Street, Parkville, Vic. 3050, Australia. Email: Stephen.Davis@mh.org.au

Received 4 September 2013; accepted 16 September 2013.

Abstract

This pilot study in a prospective cohort of 20 cryptogenic stroke patients showed that a significant proportion has paroxysmal atrial fibrillation undetected by 24-h Holter monitoring. However, longer monitoring with 28-day Holter was poorly tolerated and still insufficiently sensitive for paroxysmal atrial fibrillation detection. Further studies are urgently needed to elucidate the optimal timing, method and duration of cardiac rhythm monitoring following ischaemic stroke.

ARTICLE IN PRESS

Finding atrial fibrillation in stroke patients: Randomized evaluation of enhanced and prolonged Holter monitoring—Find-AF_{RANDOMISED} —rationale and design

Mark Weber-Krüger, MD, ^a Götz Gelbrich, PhD, ^{b,c} Raoul Stahrenberg, MD, ^d Jan Liman, MD, ^e Pawel Kermer, MD, ^f Gerhard F. Hamann, MD, ^g Joachim Seegers, MD, ^h Klaus Gröschel, MD, ^{i,j} and Rolf Wachter, MD ^{a,j}, on behalf of the Find-AF_{RANDOMISED} investigators *Göttingen*, *Wiirzburg*, *Nortbeim*, *Sande*, *Giinzburg*, *Regensburg and Mainz*, *Germany*


Background Detecting paroxysmal atrial fibrillation (AF) in patients with ischemic strokes presenting in sinus rhythm is challenging because episodes are often short, occur randomly, and are frequently asymptomatic. If AF is detected, recurrent thromboembolism can be prevented efficiently by oral anticoagulation. Numerous uncontrolled studies using various electrocardiogram (ECG) devices have established that prolonged ECG monitoring increases the yield of AF detection, but most established procedures are time-consuming and costly. The few randomized trials are mostly limited to cryptogenic strokes. The optimal method, duration, and patient selection remain unclear. Repeated prolonged continuous Holter ECG monitoring to detect paroxysmal AF within an unspecific stroke population may prove to be a widely applicable, effective secondary prevention strategy.

Study Design Find-AF_{RANDOMISED} is a randomized and controlled prospective multicenter trial. Four hundred patients 60 years or older with manifest (symptoms ≥24 hours or acute computed tomography/magnetic resonance imaging lesion) and acute (symptoms ≤7 days) ischemic strokes will be included at 4 certified stroke centers in Germany. Those with previously diagnosed AF/flutter, indications/contraindications for oral anticoagulation, or obvious causative blood vessel pathologies will be excluded. Patients will be randomized 1:1 to either enhanced and prolonged Holter ECG monitoring (10 days at baseline and after 3 and 6 months) or standard of care (≥24-hour continuous ECG monitoring, according to current stroke guidelines). All patients will be followed up for at least 12 months.

Outcomes The primary end point is newly detected AF (≥30 seconds) after 6 months, confirmed by an independent adjudication committee. We plan to complete recruitment in autumn 2014. First results can be expected by spring 2016. (Am Heart J 2014;0:1-9.)



Partir dos sintomas ou partir do sinal eletrocardiográfico?



Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis

Luciano A Sposato, Lauren E Cipriano, Gustavo Saposnik, Estefanía Ruíz Vargas, Patricia M Riccio, Vladimir Hachinski

Sobre o monitor implantável



Reveal

Avaliação de síncope



Reveal Plus 2000

Automatização



Reveal DX 2007

Maior Bateria (3 anos) Maior capacidade de memória (50 minutos)log para taquicardia e CDI

Acesso remoto e uso em RNM




Reveal XT 2009


Detecção de FA Compasso




Marcadores de Sense - Reveal XT



Ritmos Cardíacos no Programador




Plotagem dos intervalos RR em Lorenz Plot




Lorenz Plot:

- •961 bins
- •40ms x -40ms
- •-620 ms to +620ms



Como se apresentam os Ritmos no monitor de eventos implantável



Cryptogenic Stroke and Underlying Atrial Fibrillation

Tommaso Sanna, M.D., Hans-Christoph Diener, M.D., Ph.D., Rod S. Passman, M.D., M.S.C.E., Vincenzo Di Lazzaro, M.D., Richard A. Bernstein, M.D., Ph.D., Carlos A. Morillo, M.D., Marilyn Mollman Rymer, M.D., Vincent Thijs, M.D., Ph.D., Tyson Rogers, M.S., Frank Beckers, Ph.D., Kate Lindborg, Ph.D., and Johannes Brachmann, M.D., for the CRYSTAL AF Investigators* N ENGL J MED 370;26 NEJM.ORG JUNE 26, 2014


- Pacientes com AVC criptogênico
- Seguimento convencional vs monitor implantável
 - convencional = ECG +Holter 24h e Telemetria 72h
- Seguimento por 6 meses, 12 meses e 36 meses

6 meses

Cryptogenic Stroke and Underlying Atrial Fibrillation

Tommaso Sanna, M.D., Hans-Christoph Diener, M.D., Ph.D., Rod S. Passman, M.D., M.S.C.E., Vincenzo Di Lazzaro, M.D., Richard A. Bernstein, M.D., Ph.D., Cardos A. Morillo, M.D., Marilyn Mollman Rymer, M.D., Vincent Thijs, M.D., Ph.D., Tyon Rogers, M.S., Frank Beckers, Ph.D., Kate Lindborg, Ph.D., and Johannes Brachmann, M.D., for the CRYSTAL AF Investigators*

Detecção de Fibrilação Atrial em 6 meses




12 meses

Cryptogenic Stroke and Underlying Atrial Fibrillation

Tommaso Sanna, M.D., Hans-Christoph Diener, M.D., Ph.D., Rod S. Passman, M.D., M.S.C.E., Vincenzo Di Lazzaro, M.D., Richard A. Bernstein, M.D., Ph.D., Cardos A. Morillo, M.D., Marilyn Mollman Rymer, M.D., Vincent Thijs, M.D., Ph.D., Tyon Rogers, M.S., Frank Beckers, Ph.D., Kate Lindborg, Ph.D., and Johannes Brachmann, M.D., for the CRYSTAL AF Investigators*


Detecção de Fibrilação Atrial em 12 meses



36 meses

Cryptogenic Stroke and Underlying Atrial Fibrillation

Tommaso Sanna, M.D., Hans-Christoph Diener, M.D., Ph.D., Rod S. Passman, M.D., M.S.C.E., Vincenzo Di Lazzaro, M.D., Richard A. Bernstein, M.D., Ph.D., Cardos A. Morillo, M.D., Marilyn Mollman Rymer, M.D., Vincent Thijs, M.D., Ph.D., Theory Rogers, M.S., Frank Beckers, Ph.D., Kate Lindborg, Ph.D., and Johannes Brachmann, M.D., for the CRYSTAL AF Investigators*



Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis

Luciano A Sposato, Lauren E Cipriano, Gustavo Saposnik, Estefanía Ruíz Vargas, Patricia M Riccio, Vladimir Hachinski

Summary

Background Among patients with atrial fibrillation, the risk of stroke is highest for those with a history of stroke; however, oral anticoagulants can lower the risk of recurrent stroke by two-thirds. No consensus has been reached about how atrial fibrillation should be investigated in patients with stroke, and its prevalence after a stroke remains uncertain. We did a systematic review and meta-analysis to estimate the proportion of patients newly diagnosed with atrial fibrillation after four sequential phases of cardiac monitoring after a stroke or transient ischaemic attack.

Methods We searched PubMed, Embase, and Scopus from 1980 to June 30, 2014. We included studies that provided the number of patients with ischaemic stroke or transient ischaemic attack who were newly diagnosed with atrial fibrillation. We stratified cardiac monitoring methods into four sequential phases of screening: phase 1 (emergency room) consisted of admission electrocardiogram (ECG); phase 2 (in hospital) comprised serial ECG, continuous inpatient ECG monitoring, continuous inpatient cardiac telemetry, and in-hospital Holter monitoring; phase 3 (first ambulatory period) consisted of ambulatory Holter; and phase 4 (second ambulatory period) consisted of mobile cardiac outpatient telemetry, external loop recording, and implantable loop recording. The primary endpoint was the proportion of patients newly diagnosed with atrial fibrillation for each method and each phase, and for the sequential combination of phases. For each method and each phase, we estimated the summary proportion of patients diagnosed with post-stroke atrial fibrillation using random-effects meta-analyses.

Findings Our systematic review returned 28 290 studies, of which 50 studies (comprising 11658 patients) met the criteria for inclusion in the meta-analyses. The summary proportion of patients diagnosed with post-stroke atrial fibrillation was 7.7% (95% CI 5.0–10.8) in phase 1, 5.1% (3.8–6.5) in phase 2, 10.7% (5.6–17.2) in phase 3, and 16.9% (13.0–21.2) in phase 4. The overall atrial fibrillation detection yield after all phases of sequential cardiac monitoring was 23.7% (95% CI 17.2–31.0).


Interpretation By sequentially combining cardiac monitoring methods, atrial fibrillation might be newly detected in nearly a quarter of patients with stroke or transient ischaemic attack. The overall proportion of patients with stroke who are known to have atrial fibrillation seems to be higher than previously estimated. Accordingly, more patients could be treated with oral anticoagulants and more stroke recurrences prevented.

Funding Heart and Stroke Foundation of Canada, and Natural Science and Engineering Research Council of Canada.

Lancet Neurol 2015

Published Online March 4, 2015 http://dx.doi.org/10.1016/ S1474-4422(15)70027-X


Detecção com Holter intrahospitalar



Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis

Proporção dos pacientes com FA diagnosticada

Detecção com ECG seriado




Proporção dos pacientes com FA diagnosticada

Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis

Luciano A Sposato, Lauren E Cipriano, Gustavo Saposnik, Estefanía Ruíz Varqas, Patricia M Riccio, Vladimir Hachinski

Detecção com Telemetria




Proporção dos pacientes com FA diagnosticada

Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis

Luciano A Sposato, Lauren E Cipriano, Gustavo Saposnik, Estefanía Ruíz Vargas, Patricia M Riccio, Vladimir Hachinski

Holter ambulatorial



Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis

Luciano A Sposato, Lauren E Cipriano, Gustavo Saposnik, Estefanía Ruíz Vargas, Patricia M Riccio, Vladimir Hachinski







Seção Médica de Eletrofisiologia Clínica e Arritmias Cardíacas Instituto Dante Pazzanese de Cardiologia

Equipe de Eletrofisiologia Pediátrica

Obrigado!!!

rogerio and a laft @arritmia on line.com. br

Download em

www.arritmiaonline.com.br

